Human CD24 VLP Protein
Catalog No: CD24-HP001
- Species
- Human
- Expression System
- HEK293
- Activity
- Activity verified
Product overview
Recombinant Human CD24 VLP Protein is produced in HEK293 cells and contains the Ser27-Gly59 region of human CD24. The product is supplied as a lyophilized preparation for research use.
Product Details
- Molecular Aliases
- CD24; CD24A; CD 24; FLJ22950; FLJ43543; MGC75043
- Protein Length
- Ser27-Gly59
- Expression System
- HEK293
- Theoretical Molecular Weight
- 5.0 kDa
- Purity
- >90% as determined by HPLC
- Endotoxin
- <1 EU/μg as determined by the LAL method
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered PBS, pH 7.4. Normally 8% trehalose is added as a protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- Store at -20°C or below for up to 12 months. Aliquot after reconstitution and minimize freeze-thaw cycles.
- Reconstitution Advice
- Reconstitute with distilled water. Refer to the Certificate of Analysis for the recommended volume.
Data Display
Immobilized Human CD24 VLP at 0.5 μg/mL (100 μL/well). The dose-response curve for Anti-CD24 Antibody, hFc Tag gave an EC50 of 3.7 ng/mL by ELISA (QC test).
Background
CD24 is a sialoglycoprotein expressed on most B lymphocytes and differentiating neuroblasts, as well as on neutrophils and their precursors from the myelocyte stage onward. CD24 is overexpressed in multiple human cancers and is being investigated as a potential therapeutic target.
References
- Barkal AA et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019. doi:10.1038/s41586-019-1456-0.
- Sun F et al. Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design. Oncotarget. 2017;8(31):51238-51252.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.